Scope
The IDSA complicated-UTI guideline uses illness severity, resistance risk, individual safety factors and selected local susceptibility data to guide initial treatment. It supports culture-directed narrowing, an oral switch once suitable, and shorter courses in clinically improving patients receiving effective therapy, while identifying groups poorly represented in trials.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose initial therapy using severity and individual risk
- Initially distinguish suspected complicated UTI with sepsis from disease without sepsis. Then assess prior resistant organisms, other patient-specific safety considerations and, for sepsis, a suitable local antibiogram; the guideline recommends a staged assessment rather than a single universal antibiotic. [1]
- For sepsis caused by complicated UTI, conditionally prioritize a third- or fourth-generation cephalosporin, carbapenem, piperacillin–tazobactam or fluoroquinolone after the individual assessment. Newer agents or older aminoglycosides are not the default first choices under this recommendation. [1]
- When complicated UTI is suspected without sepsis, conditionally prioritize a third- or fourth-generation cephalosporin, piperacillin–tazobactam or fluoroquinolone after individual assessment, rather than routinely starting a carbapenem, newer agent or older aminoglycoside. [1]
- Broader coverage beyond Enterobacterales may be considered in sepsis if the urinary source is uncertain or Pseudomonas, enterococci or MRSA is suspected. For selected patients without sepsis, oral options such as trimethoprim–sulfamethoxazole or amoxicillin–clavulanate are less studied and appropriate only in selected circumstances. [1]
- Conditionally avoid an antibiotic to which a prior urinary pathogen was resistant, giving more recent cultures greater relevance. Also conditionally avoid fluoroquinolones after exposure to that class within the past 12 months; recent exposure may be more informative than distant exposure. [1]
- Account for allergy risk, contraindications and drug interactions when choosing empiric therapy to avoid preventable harm. This is a good-practice statement rather than a claim that one antibiotic is safest for every patient. [1]
Use susceptibility information in the correct context
- For urinary-source sepsis, use an antibiogram to further tailor therapy only if it is local, recent and relevant: from the same facility, based on the prior 12 months, and derived from a similar patient population. [1]
- When a suitable antibiogram is used, consider an agent with at least 90% susceptibility among the relevant organisms in septic shock, or at least 80% in sepsis without shock. These are modelling-based cutoffs, not universal thresholds for every UTI. [1]
- The guideline makes no specific recommendation for antibiogram-based tailoring in complicated UTI without sepsis. Once cultures identify the pathogen and susceptibility, conditionally narrow to a targeted effective antibiotic rather than continuing broad empiric therapy throughout. [1]
Require improvement, oral feasibility and an effective oral agent
- For complicated UTI initially treated intravenously, conditionally switch to oral therapy when the patient is clinically improving, can take oral medication and has an effective oral option. Effectiveness requires activity against the organism and therapeutic levels in urine and involved tissue. [1]
- Individualize an oral-switch plan for groups mostly excluded from supporting trials, including indwelling urinary catheters, sepsis or shock, immunocompromise, severe renal impairment, and structural or functional urinary-tract abnormalities. [1]
- An oral switch is also conditionally suggested for improving complicated UTI with Gram-negative bacteraemia when oral treatment is feasible and effective. Supporting trials mostly switched after fever resolved, haemodynamic stability and source control, including relief of obstruction; the agent must achieve therapeutic blood as well as urine and tissue levels. [1]
Count effective treatment days and reassess non-improvement
- In complicated UTI with clinical improvement on effective treatment, conditionally use 5–7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone rather than 10–14 days. Count duration from the first effective treatment day, not necessarily the first antibiotic dose. [1]
- Do not automatically apply short-course results to excluded high-risk groups: urinary catheters, severe sepsis, immunocompromise, urinary abscess, CKD, bacterial prostatitis, complete obstruction or urological procedures may require individualized duration. [1]
- Improving complicated UTI with Gram-negative bacteraemia can conditionally receive 7 rather than 14 days of effective therapy. Count from the first effective day; bloodstream, urine and relevant tissue exposure and pathogen susceptibility remain necessary. [1]
- Febrile UTI in men with suspected acute bacterial prostatitis, including bacteremic presentations, may benefit from 10–14 days, but optimal duration is uncertain. Investigate an ongoing source needing control if improvement is not prompt; evidence for short oral beta-lactam courses is more limited and higher doses may be needed. [1]
Limitations and use
- This summary follows the accessible guideline recommendation text; graphical classification boxes and antibiotic-dose tables are not reconstructed. The revised classification is intended to guide treatment, not serve as a diagnostic rule. Chronic urinary-symptom diagnosis and treatment are outside scope. Trial exclusions and suspected prostatitis can require individualized treatment rather than automatic application of the shortest course.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Complicated urinary tract infections
Selected recommendation material consulted
Publication details
- Issuing organisation
- IDSA
- First published
- 17 July 2025
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.